Nifty
Sensex
:
:
11767.75
40145.50
-162.60 (-1.36%)
-540.00 (-1.33%)

Pharmaceuticals & Drugs

Rating :
70/99  (View)

BSE: 524774 | NSE: Not Listed

908.70
22.70 (2.56%)
26-Oct-2020 | 4:01PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  886.00
  •  925.00
  •  886.00
  •  886.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4815
  •  43.75
  •  925.00
  •  220.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 561.40
  • 44.34
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 586.47
  • 0.19%
  • 5.18

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 73.81%
  • 1.38%
  • 22.04%
  • FII
  • DII
  • Others
  • 0%
  • 0.00%
  • 2.77%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.71
  • 9.59
  • 10.22

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.69
  • -0.98
  • -0.61

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.97
  • -1.44
  • -5.67

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 35.92

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.27
  • 0.84
  • 3.82

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.13
  • 3.50
  • 16.04

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
42
41
4%
35
0
0
37
34
9%
37
39
-4%
Expenses
29
32
-10%
33
0
0
34
27
26%
33
32
3%
EBITDA
13
8
59%
2
0
0
3
7
-56%
4
7
-38%
EBIDTM
32%
21%
6%
0%
9%
21%
12%
18%
Other Income
2
1
61%
1
0
0
1
1
63%
1
2
-42%
Interest
1
0
25%
1
0
0
1
1
0%
1
1
27%
Depreciation
2
2
12%
2
0
0
2
2
27%
2
1
32%
PBT
13
7
74%
0
0
0
2
6
-71%
3
7
-59%
Tax
4
2
57%
1
0
0
1
2
-67%
0
2
-83%
PAT
9
5
81%
0
0
-
1
4
-72%
2
4
-47%
PATM
22%
13%
-1%
0%
3%
12%
6%
11%
EPS
15.14
8.38
81%
-0.30
0.00
-
1.82
6.57
-72%
3.78
7.13
-47%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 20
Mar 19
Net Sales
-
152
153
Net Sales Growth
-
-1%
 
Cost Of Goods Sold
-
64
63
Gross Profit
-
87
91
GP Margin
-
58%
59%
Total Expenditure
-
132
121
Power & Fuel Cost
-
10
9
% Of Sales
-
7%
6%
Employee Cost
-
24
21
% Of Sales
-
16%
14%
Manufacturing Exp.
-
17
13
% Of Sales
-
11%
9%
General & Admin Exp.
-
6
5
% Of Sales
-
4%
3%
Selling & Distn. Exp.
-
5
5
% Of Sales
-
3%
3%
Miscellaneous Exp.
-
5
5
% Of Sales
-
3%
3%
EBITDA
-
20
32
EBITDA Margin
-
13%
21%
Other Income
-
3
4
Interest
-
3
3
Depreciation
-
8
6
PBT
-
12
28
Tax
-
4
7
Tax Rate
-
31%
27%
PAT
-
8
20
PAT before Minority Interest
-
8
20
Minority Interest
-
0
0
PAT Margin
-
6%
13%
PAT Growth
-
-59%
 
EPS
-
13.45
32.47

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Shareholder's Funds
99
92
Share Capital
3
3
Total Reserves
96
89
Non-Current Liabilities
12
12
Secured Loans
8
8
Unsecured Loans
0
0
Long Term Provisions
2
1
Current Liabilities
49
45
Trade Payables
21
16
Other Current Liabilities
6
6
Short Term Borrowings
15
15
Short Term Provisions
7
8
Total Liabilities
159
149
Net Block
68
61
Gross Block
92
74
Accumulated Depreciation
24
13
Non Current Assets
73
63
Capital Work in Progress
0
0
Non Current Investment
0
0
Long Term Loans & Adv.
5
2
Other Non Current Assets
0
0
Current Assets
87
86
Current Investments
11
9
Inventories
28
19
Sundry Debtors
26
33
Cash & Bank
3
3
Other Current Assets
19
7
Short Term Loans & Adv.
12
16
Net Current Assets
38
41
Total Assets
159
149

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Cash From Operating Activity
20
9
PBT
12
28
Adjustment
12
8
Changes in Working Capital
0
-19
Cash after chg. in Working capital
24
16
Interest Paid
0
0
Tax Paid
-4
-7
Other Direct Exp. Paid
0
0
Extra & Other Items
0
0
Cash From Investing Activity
-21
-10
Net Fixed Assets
-7
Net Investments
-6
Others
-8
Cash from Financing Activity
0
0
Net Cash Inflow / Outflow
0
-1
Opening Cash & Equivalents
1
1
Closing Cash & Equivalent
0
1

Financial Ratios

Standalone /

Consolidated
Description
Mar 20
Mar 19
Book Value (Rs.)
160
149
ROA
5%
13%
ROE
9%
22%
ROCE
12%
25%
Fixed Asset Turnover
1.83
2.07
Receivable days
71
79
Inventory Days
56
44
Payable days
48
48
Cash Conversion Cycle
79
75
Total Debt/Equity
0.29
0.29
Interest Cover
6
12

News Update


  • ICRA reaffirms NGL Fine-Chem’s long term rating at BBB+
    28th Sep 2020, 12:05 PM

    The credit rating agency has also reaffirmed the short term rating is A2

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.